Clinical trial NCT02889224: In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
Official title: In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cushing's Syndrome
Keywords: Obesity
Cortisol
Hydrocortisone
Endocannabinoïds
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2016-09-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Working hypothesis: the interactions between the endogenous endocannabinoïds (ECS) - and cortisol, the end product of the Hypothalamo-Pituitary-Adrenal (HPA) axis may play a role in the pathophysiology of Cushing's syndrome.

The investigators speculate that:

* acute or chronic variations in plasma cortisol may induce changes in the activity of the ECS
* that there is a circadian rhythm of the ECS driven by the rythm of plasma cortisol

Detailed description: The study aim to identify the relationship between the ECS and the HPA axis in humans with a main objective to assess if Cushing's syndrome induces changes in the ECS activity.

For this purpose:

1. the investigors will compare plasma levels of ECS between obese controls and patients with Cushing's syndrome
2. the investigors will compare plasma levels of ECS in patients with Cushing's syndrome before and immediately after curative surgery
3. the investigors will compare plasma levels of ECS in patients with hypoadrenalism before and after the intake of substitutive doses of hydrocortisone
4. the investigors will evaluate the plasma levels of ECS during a short synacthen test in healthy subjects.

Eligibility criteria: Inclusion Criteria:

For all patients groups:

* Age ≥ 18,
* Social security.

" Hypercortisolism " group:

* 18 \< BMI \< 40 kg/m2,
* Cushing's syndrome in front of :
* impaired 1 mg dexamethasone test (08:00 A.M. cortisol \> 50 nmol/L)
* qualitative and quantitative disrupted circadian rhythm of cortisol with increased plasma concentrations
* free urinary cortisol upper normal range (90 µg/24H),
* Hypercortisolism that can be treated with surgery (adrenal adenoma treated with adrenalectomy or Cushing disease treated with pituitary surgery).

" Obese " group:

* Obese patients: 30 \< BMI \< 40 kg/m2,
* Normal HPA axis function:
* 08:00 A.M. cortisol \> 250 nmol/L and peak above 550 nmol/L after 1 mg SST,
* Normal 24H free urinary cortisol and dexamethasone test. " Control " group:
* Lean or overweight patients (18 \< BMI \< 30 kg/m2),
* Non cortisol secreting pituitary or adrenal tumor,
* Patient in whom a biological evaluation of the HPA axis is recommended.

" Hydrocortisone " group:

* Lean or overweight patients (18 \< BMI \< 30 kg/m2),
* Primary or secondary adrenal insufficiency,
* With a need for hydrocortisone supplementation.

Exclusion Criteria:

* Patients with eating disorders, major depressive disorders or psychiatric disorders other than Cushing's syndrome,
* Cannabis consumption, alcoholism or drug addiction,
* Active smoking,
* cortisone treatment other than hydrocortisone,
* Pregnancy or feeding,
* Surgery for obesity,
* Incapability,
* Pathology that is life-threatening in the short term,
* Any situation that interfere with study or is risked for patient.

Primary outcomes:
measure: Fluctuations of 2-AG (2-arachidonoyl-Glycérol) plasma concentration in relationship to cortisol plasma concentration in obese arm compare to hypercortisolism arm.
timeFrame: Baseline
Secondary outcomes:
measure: Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds associated with variations of plasma cortisol in hypercortisolism arm
timeFrame: Baseline and day 6
measure: Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds associated with variations of plasma cortisol in hydrocortisone arm
timeFrame: Baseline
measure: Measurement of plasma concentration of AEA (Anandamide), OEA (Oleoyl-EthanolAmide) and PEA (Palmitoyl-EthanolAmide) endocannabinoïds in control arm who have no cortisol production problem.
timeFrame: Baseline
Other outcomes:
Locations:
city: Pessac
country: France
facility: Service d'Endocrinologie, Hopital Haut-Leveque
Study officials:
affiliation: University Hospital, Bordeaux
name: Paul PEREZ, MD
role: STUDY_CHAIR
References: